IMP321, Keytruda Combo Trial Receives OK to Open Last Patient Group
News
Prima Biomed, an Australian biotechnology company developing immunotherapies for cancer and autoimmune diseases, announced it has received approval for the third cohort of its Phase 1 melanoma trial (NCT02676869), ... Read more